1-Tert-butyl-3-(difluoromethyl)benzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Tert-butyl-3-(difluoromethyl)benzene
• 英文别名: 1-tert-butyl-3-(difluoromethyl)benzene
• 化学式: C₁₁H₁₄F₂
• 分子量: 184.23
• InChiKey: CGGYDRFUPATCMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Revolution Medicines, Inc.

  公开号：US20210139517A1

  公开（公告）日：2021-05-13

  The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

  本公开涉及SOS1的调节剂及其在治疗疾病中的应用。还公开了包含相同成分的药物组合物。
• SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20200392130A1

  公开（公告）日：2020-12-17

  Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

  取代的吡唑并[4,3-b]吡啶作为GluN2B受体配体。这类化合物可用于GluN2B受体调节，以及用于治疗由GluN2B受体活性介导的疾病状态、疾病和症状的药物组合物和方法。
• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Calistoga LLC

  公开号：US20160016915A1

  公开（公告）日：2016-01-21

  The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which n, m, R 1 , R 2 , and R 3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3Kδ. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3Kδ.

  本公开提供式(I)的磷脂酰肌醇3-激酶（PI3K）抑制剂，或其药学上可接受的盐，其中n，m，R1，R2和R3如本文所定义。这些化合物对于治疗由一个或多个PI3K同工酶介导的疾病，如PI3Kδ，是有用的。本公开进一步提供包括式(I)的化合物或其药学上可接受的盐的制药组合物，并使用这些化合物和组合物治疗由一个或多个PI3K同工酶介导的疾病，如PI3Kδ的方法。
• Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
  申请人：PHENEX DISCOVERY VERWALTUNGS-GMBH

  公开号：US11078168B2

  公开（公告）日：2021-08-03

  The invention provides modulators of indoleamine 2,3-dioxygenase (IDO1) and their use in the prophylaxis and/or treatment of IDO1-mediated diseases. Specifically, the present invention provides compounds according to Formula (I) an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof.

  本发明提供了吲哚胺 2,3-二氧化酶（IDO1）的调节剂及其在预防和/或治疗 IDO1 介导的疾病中的用途。具体而言，本发明提供了符合式（I）的化合物及其对映体、非对映体、同分异构体或药学上可接受的盐。
• Bicyclic heteroaryl compounds and uses thereof
  申请人：Revolution Medicines, Inc.

  公开号：US11168102B1

  公开（公告）日：2021-11-09

  The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same. Modulators of SOS1 have the following general structure of the Formula (II), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the variables are as defined herein.

  本公开涉及 SOS1 的调节剂及其在疾病治疗中的应用。此外，还公开了由其组成的药物组合物。SOS1 的调节剂具有如下一般结构式 (II)、 或其药学上可接受的盐或立体异构体，其中变量如本文所定义。